Dilating the cervix medically to overcome an unsatisfactory colposcopy: 5 year follow up.
OBJECTIVE
To examine the long term results of placing a hydroscopic sponge in the cervix to expose high lesions and overcome an unsatisfactory colposcopic examination.


METHODS
Forty-one women presenting with their first abnormal smear but an unsatisfactory colposcopy were offered medical dilation of the cervix with Lamicel. These women had local ablative treatment and were followed for 5 years to establish the risk of recurrent disease after medical dilation. For comparison we measured the risk of recurrence after a cone biopsy performed as primary treatment for women attending a different hospital in the same city.


RESULTS
Medical dilation was unacceptable or failed in 16 of the 41 women. It was initially successful at exposing the entire transformation zone and sparing 25 women a cone biopsy. Ten of these presented with recurrent disease requiring a cone biopsy within 5 years. Two cases were lost to follow up leaving 13 out of a total of 38 women who ultimately avoided a cone biopsy. The recurrent disease rate despite local treatment following medical dilation is 43%. The recurrent disease rate in the city following a cone biopsy is 20%.


CONCLUSIONS
Although medical dilation of the cervix may permit lesions in the canal to be visualised, follow up is difficult and the risk of further disease is high. It is not recommended as a routine.
Department of Obstetrics and Gynaecology, Leeds University, UK.
N
N
Johnson
J
J
Brady
D001672:Biocompatible Materials / Q000009:adverse effects / Q000494:pharmacology*; D002584:Cervix Uteri / Q000187:drug effects / Q000473:pathology* / Q000601:surgery; D003127:Colposcopy; D019092:Conization; D004106:Dilatation / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy; D008278:Magnesium Sulfate / Q000009:adverse effects / Q000494:pharmacology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery; D011142:Polyvinyl Alcohol / Q000009:adverse effects / Q000494:pharmacology*; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000601:surgery; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000473:pathology* / Q000601:surgery
D001672:Biocompatible Materials; C034860:Lamicel; D008278:Magnesium Sulfate; D011142:Polyvinyl Alcohol